- Home
- ADVM vs ACCS Comparison
ADVM vs ACCS Comparison
Compare ADVM & ACCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADVM
- ACCS
- Stock Information
- Founded
- ADVM 2006
- ACCS 1988
- Country
- ADVM United States
- ACCS United States
- Employees
- ADVM N/A
- ACCS N/A
- Industry
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- ACCS Publishing
- Sector
- ADVM Health Care
- ACCS Consumer Discretionary
- Exchange
- ADVM Nasdaq
- ACCS Nasdaq
- Market Cap
- ADVM 47.4M
- ACCS 44.2M
- IPO Year
- ADVM 2014
- ACCS N/A
- Fundamental
- Price
- ADVM $2.74
- ACCS $12.02
- Analyst Decision
- ADVM Strong Buy
- ACCS Strong Buy
- Analyst Count
- ADVM 5
- ACCS 1
- Target Price
- ADVM $23.80
- ACCS $15.00
- AVG Volume (30 Days)
- ADVM 297.2K
- ACCS 12.3K
- Earning Date
- ADVM 08-11-2025
- ACCS 08-07-2025
- Dividend Yield
- ADVM N/A
- ACCS N/A
- EPS Growth
- ADVM N/A
- ACCS N/A
- EPS
- ADVM N/A
- ACCS N/A
- Revenue
- ADVM $1,000,000.00
- ACCS $22,961,000.00
- Revenue This Year
- ADVM N/A
- ACCS $7.67
- Revenue Next Year
- ADVM $18.82
- ACCS N/A
- P/E Ratio
- ADVM N/A
- ACCS N/A
- Revenue Growth
- ADVM N/A
- ACCS 6.92
- 52 Week Low
- ADVM $1.78
- ACCS $7.79
- 52 Week High
- ADVM $10.14
- ACCS $13.35
- Technical
- Relative Strength Index (RSI)
- ADVM 59.62
- ACCS N/A
- Support Level
- ADVM $2.50
- ACCS N/A
- Resistance Level
- ADVM $2.75
- ACCS N/A
- Average True Range (ATR)
- ADVM 0.20
- ACCS 0.00
- MACD
- ADVM 0.06
- ACCS 0.00
- Stochastic Oscillator
- ADVM 82.50
- ACCS 0.00
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
About ACCS ACCESS Newswire Inc. Common Stock
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.